Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job
Symposium

Biomarkers for Immuno-Oncology: Fundamentals, Technologies and Applications for Biomarkers in Research, Translational and Clinical Development of Immuno-Oncology Therapeutics


Speakers: Terri McClanahan (Merck), Rod Prell (Genentech), Michael Angelo (Stanford), Luciana Molinero (Genentech), Manasi Shah (Second Genome), Adil Daud (UCSF), Jeff Wallin (Genentech), Jakob Dupont (OncoMed Pharmaceuticals), Selda Samakoglu (Pharmacyclics)
Organizers: Wenfeng Xu (Genentech), Jeff Wallin (Genentech), Vinita Gupta (Genentech)
Date: 2016-10-28
Time: 8:00-17:30 Pacific Time
Registration fee: (USD): Regular: $195; Between Jobs: $50; Academic: $50
Location: Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2016-10-26  (it will close sooner if the seating cap is reached)

About the Topic

[Please Note: morning coffee & light breakfast starts at 8:00am; Presentations start at 8:45am]

There has been tremendous progress in the field of immuno-oncology as checkpoint inhibitor therapy has revolutionized the treatment of many cancers. Biomarkers have played a critical role in understanding mechanism of action, stratifying patient population, discovering new targets, and guiding clinical development. This one-day symposium will introduce fundamentals, technologies, and applications for biomarkers in research, translational, and clinical development of immune-oncology therapeutics with participation from experts in both academia and biotech/pharma. This is a great opportunity to learn the latest advancements in these areas and also a chance for participants to network and collaborate.


Agenda:

  1. Maximizing the Benefit of Anti-PD1 Therapy - Terri McClanahan (Merck)
  2. Biomarker Strategies for Combination Immunotherapy – Jeff Wallin (Genentech)
  3. Biomarkers for Novel Immune Checkpoint Inhibitors – Jakob Dupont (OncoMed Pharmaceuticals)
  4. Analysis of the tumor microenvironment using high dimensional IHC and multiplexed ion beam imagining – Michael Angelo (Stanford)
  5. Biomarker for Breast Cancer Immunotherapy – Luciana Molinero (Genentech)
  6. Microbiome Biomarkers in Colorectal Cancer – Manasi Shah (Second Genome)
  7. Safety Biomarker in Pre-clinical Models – Rod Prell (Genentech)
  8. Novel T cell biomarkers for response to PD1 and PD1/CTLA4 immunotherapy – Adil Daud (UCSF)

Other Events of PBSS-San Francisco Bay:

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/23/2024; Admin Logon
 Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad